Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03870529 · ClinicalTrials.gov registry record · Early Phase 1
High Dose Vitamin A Compound in Treating Participants With Resectable Non-Small Cell Lung Cancer
A Early Phase 1 study, sponsored by Wake Forest University Health Sciences.
- Terminated
- Registry status
- Early Phase 1
- Development phase
- 20
- Enrollment target
NCT03870529 is a Early Phase 1 study that was terminated before completion, run by Wake Forest University Health Sciences. The registered enrollment target is 20 participants.
The verdict
NCT03870529, a Early Phase 1 study, was terminated before completion, sponsored by Wake Forest University Health Sciences.
- TERMINATED
- Registry status
- Early Phase 1
- Development phase
- 20 participants
- Enrollment target
Study Summary
This trial studies how well high dose vitamin A compound works in treating participants with non-small cell lung cancer that can be removed by surgery. Vitamin A compound may increase the number of germinal centers (immune centers that make antibodies mature) in tumor and lymph tissues which may be beneficial to patients with cancer.
Interventions
- PROCEDURE Therapeutic Conventional Surgery
- DRUG Vitamin A Compound
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2019-08-19 |
| Est. Completion | 2022-12-09 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03870529
The ClinicalTrials.gov registry entry for NCT03870529 describes a study currently listed as terminated, categorized as Early Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Wake Forest University Health Sciences, which has 1,140 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Therapeutic Conventional Surgery is the first listed.
NCT03870529 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03870529 about?
NCT03870529 is a clinical study titled "High Dose Vitamin A Compound in Treating Participants With Resectable Non-Small Cell Lung Cancer". This trial studies how well high dose vitamin A compound works in treating participants with non-small cell lung cancer that can be removed by surgery. Vitamin A compound may increase the number of germinal centers (immune centers that make antibodies mature) in tumor and lymph tissues which may be ...
What is the current status of trial NCT03870529?
This trial is currently terminated. It is a Early Phase 1 study. The enrollment target is 20 participants. The study started on 2019-08-19. Estimated completion is 2022-12-09.
What interventions are being tested in trial NCT03870529?
The interventions under investigation include: Therapeutic Conventional Surgery (PROCEDURE), Vitamin A Compound (DRUG).
Who is sponsoring clinical trial NCT03870529?
This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.